169 related articles for article (PubMed ID: 15837592)
1. After imatinib: new hopes for chronic myeloid leukaemia.
Bradbury J
Drug Discov Today; 2005 Apr; 10(8):536-7. PubMed ID: 15837592
[No Abstract] [Full Text] [Related]
2. Gleevec resistance: lessons for target-directed drug development.
Daley GQ
Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
[No Abstract] [Full Text] [Related]
3. [New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Liu H; Chen XG
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):561-3. PubMed ID: 17236546
[No Abstract] [Full Text] [Related]
4. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
5. Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Doggrell SA
Expert Opin Investig Drugs; 2005 Aug; 14(8):1063-6. PubMed ID: 16050798
[TBL] [Abstract][Full Text] [Related]
6. [Molecular targeting therapy for chronic myeloid leukemia].
Kimura S
Rinsho Ketsueki; 2007 Jan; 48(1):46-55. PubMed ID: 17313076
[No Abstract] [Full Text] [Related]
7. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
8. Circumventing resistance to kinase-inhibitor therapy.
Druker BJ
N Engl J Med; 2006 Jun; 354(24):2594-6. PubMed ID: 16775240
[No Abstract] [Full Text] [Related]
9. Imatinib mesylate.
Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
[No Abstract] [Full Text] [Related]
10. Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Cupri A; Consoli C; Messina L; Tirrò E; Messina A; Di Raimondo F
Leuk Res; 2009 Sep; 33(9):e157-8. PubMed ID: 19406471
[No Abstract] [Full Text] [Related]
11. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
12. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Golemovic M; Verstovsek S; Giles F; Cortes J; Manshouri T; Manley PW; Mestan J; Dugan M; Alland L; Griffin JD; Arlinghaus RB; Sun T; Kantarjian H; Beran M
Clin Cancer Res; 2005 Jul; 11(13):4941-7. PubMed ID: 16000593
[TBL] [Abstract][Full Text] [Related]
13. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
15. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Nadal E; Olavarria E
Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
[TBL] [Abstract][Full Text] [Related]
17. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K; Yamaguchi H; Tamai H; Dan K
J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
[No Abstract] [Full Text] [Related]
18. AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.
Nieborowska-Skorska M; Flis S; Skorski T
Leukemia; 2014 Dec; 28(12):2416-8. PubMed ID: 25151958
[No Abstract] [Full Text] [Related]
19. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Lamontanara AJ; Gencer EB; Kuzyk O; Hantschel O
Biochim Biophys Acta; 2013 Jul; 1834(7):1449-59. PubMed ID: 23277196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
